Literature DB >> 6322010

Central target for the behavioural effects of vasopressin neuropeptides.

D de Wied, O Gaffori, J M van Ree, W de Jong.   

Abstract

The neurohypophysial hormone vasopressin exerts antidiuretic, vasopressor and behavioural effects (for example, facilitation of memory processes). Vasopressin may alter animal behaviour via direct effect on brain processes. Recently, however, it has been suggested that vasopressin acts mainly at peripheral receptor systems and influences behavioural mechanisms by altering visceral afferent signals. We now present data showing that (1) central administration of [Arg8]vasopressin (AVP) and more potently [pGlu, Cyt]AVP(4-8), the desglycinamide derivative of a peptide generated from AVP by brain synaptic membranes, produce the behavioural effect (promotion of passive avoidance behaviour) without the pressor effect; (2) central administration of a vasopressor antagonist blocks the behavioural but not the pressor effect of systemically administered AVP; and (3) [pGlu, Cyt]AVP(4-8) induces the behavioural effect in the absence of the pressor effect. The results indicate that AVP and related peptides affect passive avoidance behaviour by a direct central action and that the structural requirement for activation of central vasopressin receptors differs from that of the peripheral cardiovascular receptors, although both can be blocked by the same vasopressor antagonist.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322010     DOI: 10.1038/308276a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  14 in total

1.  The effects of vasopressin on hippocampal slices from trained rats.

Authors:  I V Kudryashova; I E Kudryashov
Journal:  Neurosci Behav Physiol       Date:  1999 May-Jun

2.  Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain.

Authors:  K Toide; T Fujiwara; Y Iwamoto; M Shinoda; K Okamiya; T Kato
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

3.  Intranasal application of vasopressin fails to elicit changes in brain immediate early gene expression, neural activity and behavioural performance of rats.

Authors:  M Ludwig; V A Tobin; M F Callahan; E Papadaki; A Becker; M Engelmann; G Leng
Journal:  J Neuroendocrinol       Date:  2013-07       Impact factor: 3.627

4.  Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology.

Authors:  J B van Bree; S Tio; A G de Boer; M Danhof; J C Verhoef; D D Breimer
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

5.  Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease.

Authors:  T Aoyagi; T Wada; M Nagai; F Kojima; S Harada; T Takeuchi; H Takahashi; K Hirokawa; T Tsumita
Journal:  Experientia       Date:  1990-01-15

6.  Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor?

Authors:  D de Wied; J Elands; G Kovács
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

Review 7.  A critique of the vasopressin-memory hypothesis.

Authors:  A Sahgal
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Postnatal expression of V2 vasopressin receptor splice variants in the rat cerebellum.

Authors:  Karina J Vargas; José M Sarmiento; Pamela Ehrenfeld; Carolina C Añazco; Carolina I Villanueva; Pamela L Carmona; Marianne Brenet; Javier Navarro; Werner Müller-Esterl; Carlos B González
Journal:  Differentiation       Date:  2009-01-20       Impact factor: 3.880

Review 9.  Comparative tolerability of drug treatment for nocturnal enuresis in children.

Authors:  Dominik Müller; Charles C Roehr; Paul Eggert
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Predator odor-evoked BOLD activation in the awake rat: modulation by oxytocin and V₁a vasopressin receptor antagonists.

Authors:  Michael D Reed; Katherine E Price; Jonathan Archbold; Anthony Moffa; Marcelo Febo
Journal:  Brain Res       Date:  2012-12-03       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.